MEK‐ERK is involved in SUMO‐1 foci formation on apoptosis
暂无分享,去创建一个
T. Kasahara | Y. Sonoda | Y. Mishima | K. Hatake | Natsuhiko Sugimura | Y. Terui | Y. Mishima | Kiyotsugu Kojima | R. Utsubo-Kuniyoshi | Akiko Rokudai | K. Kojima
[1] T. Sakurai,et al. Blockade of bulky lymphoma‐associated CD55 expression by RNA interference overcomes resistance to complement‐dependent cytotoxicity with rituximab , 2006, Cancer science.
[2] B. Choi,et al. Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. , 2004, Neurotoxicology.
[3] Junying Yuan,et al. Dual Role of Sumoylation in the Nuclear Localization and Transcriptional Activation of NFAT1* , 2004, Journal of Biological Chemistry.
[4] R. Hipskind,et al. SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1 , 2004, The Journal of cell biology.
[5] A. Ishisaki,et al. Expressions of inhibitory Smads, Smad6 and Smad7, are differentially regulated by TPA in human lung fibroblast cells. , 2004, Biochemical and biophysical research communications.
[6] S. Müller,et al. SUMO: a regulator of gene expression and genome integrity , 2004, Oncogene.
[7] T. Hofmann,et al. Body language: the function of PML nuclear bodies in apoptosis regulation , 2003, Cell Death and Differentiation.
[8] T. Ueda,et al. Down-regulation of the Mitochondrial Translation System during Terminal Differentiation of HL-60 cells by 12-O-Tetradecanoyl-1-phorbol-13-acetate , 2003, Journal of Biological Chemistry.
[9] H. Saitoh,et al. The SUMO pathway is required for selective degradation of DNA topoisomerase IIβ induced by a catalytic inhibitor ICRF‐1931 , 2003, FEBS letters.
[10] Andrew D Sharrocks,et al. Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. , 2003, Molecular cell.
[11] M. Nakao,et al. The Aryl Hydrocarbon Receptor Nuclear Transporter Is Modulated by the SUMO-1 Conjugation System* , 2002, The Journal of Biological Chemistry.
[12] Y. Taketani,et al. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin , 2002, Oncogene.
[13] Xi Zheng,et al. Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis. , 2002, Nucleic acids research.
[14] S. Minucci,et al. PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage , 2002, Oncogene.
[15] Pier Paolo Pandolfi,et al. The Role of PML in Tumor Suppression , 2002, Cell.
[16] A. Dejean,et al. SUMO: of branched proteins and nuclear bodies , 2001, Oncogene.
[17] L. Liu,et al. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. , 2001, Cancer research.
[18] N. Holbrook,et al. Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.
[19] Leroy F. Liu,et al. SUMO-1 Conjugation to Human DNA Topoisomerase II Isozymes* , 2000, The Journal of Biological Chemistry.
[20] Pier Paolo Pandolfi,et al. The transcriptional role of PML and the nuclear body , 2000, Nature Cell Biology.
[21] P. Pandolfi,et al. Role of SUMO-1-modified PML in nuclear body formation. , 2000, Blood.
[22] E. Nishida,et al. Nuclear Export of Map Kinase (ERK) Involves a Map Kinase Kinase (Mek-Dependent) Active Transport Mechanism , 2000, The Journal of cell biology.
[23] I. Weinstein,et al. The protein kinase C β–specific inhibitor LY379196 blocks TPA‐induced monocytic differentiation of HL60 cells the protein kinase C β–specific inhibitor LY379196 blocks TPA‐induced monocytic differentiation of HL60 cells , 2000, Molecular carcinogenesis.
[24] Yongsok Kim,et al. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[25] G. Capranico,et al. DNA sequence selectivity of topoisomerases and topoisomerase poisons. , 1998, Biochimica et biophysica acta.
[26] M. Yanagida,et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. , 1998, Experimental cell research.
[27] E. Goldsmith,et al. Phosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation , 1998, Cell.
[28] S. Goueli,et al. Sustained Activation of the Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway Is Required for Megakaryocytic Differentiation of K562 Cells* , 1997, The Journal of Biological Chemistry.
[29] G. Hayward,et al. Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lymphocyte cell types , 1996, Journal of virology.
[30] E. Krebs,et al. Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. , 1994, The Journal of biological chemistry.
[31] G. Johnson,et al. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. , 1994, Science.
[32] J. Uitto,et al. Differential cytokine regulation of type I and type VII collagen gene expression in cultured human dermal fibroblasts. , 1994, The Journal of biological chemistry.
[33] W. Vainchenker,et al. Myeloid and megakaryocytic properties of K-562 cell lines. , 1983, Cancer research.
[34] P. Edwards,et al. Erythroid properties of K562 cells. Effect of hemin, butyrate and TPA induction. , 1983, Experimental cell research.